Idenix Pharmaceuticals (IDIX) Tops Q4 View
More News related to IDIX
- Idenix Pharmaceuticals to Present at the Third Annual JMP Securities Healthcare Focus Conference
- Idenix Pharmaceuticals (IDIX) Files $100M Offering
- Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
- Idenix Pharmaceuticals to Present at the 2008 Thomas Weisel Healthcare Conference
- Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
More News related to Earnings
- Advanced Medical Optics (EYE) Granted FDA Premarket Approval of Healon D(R) Viscoelastic
- GTC Biotherapeutics (GTCB) Announces FDA Accepts ATryn(R) BLA Filing
- Genentech and OSI Phama Said Avastin/Tarceva Combo Fails As Second-Line Treatment For Lung Cancer
Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) reports a Q4 loss of $0.31, 8 cents better than the analyst estimate of ($0.43). Revenues for the quarter were $12.6 million, versus the consensus of $10.08 million.
Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases. [bcs]
Related Categories
EarningsStocks Mentioned
-0.14Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
